Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.

McEwan P, Ward T, Yuan Y, Kim R, L'italien G.

Hepatology. 2013 Jul;58(1):54-64. doi: 10.1002/hep.26304. Epub 2013 May 27.

PMID:
23389841
2.

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM.

Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378. Epub 2011 Nov 4.

3.

Economic model of a birth cohort screening program for hepatitis C virus.

McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC.

Hepatology. 2012 May;55(5):1344-55. doi: 10.1002/hep.25510. Epub 2012 Mar 18.

PMID:
22135116
4.

Cost-effectiveness of screening for chronic hepatitis C infection in the United States.

Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE.

Clin Infect Dis. 2013 May;56(10):1382-93. doi: 10.1093/cid/cit069. Epub 2013 Feb 7.

PMID:
23392392
5.

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW.

Clin Infect Dis. 2015 Jul 15;61(2):157-68. doi: 10.1093/cid/civ220. Epub 2015 Mar 16.

PMID:
25778747
6.

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.

Chhatwal J, Kanwal F, Roberts MS, Dunn MA.

Ann Intern Med. 2015 Mar 17;162(6):397-406. doi: 10.7326/M14-1336.

7.

Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.

Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M.

Transpl Int. 2013 May;26(5):527-34. doi: 10.1111/tri.12085. Epub 2013 Mar 21.

8.
9.

Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States.

Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD.

PLoS One. 2013;8(3):e58975. doi: 10.1371/journal.pone.0058975. Epub 2013 Mar 22.

10.

Hepatitis C: an economic evaluation of extended treatment with interferon.

Shiell A, Brown S, Farrell GC.

Med J Aust. 1999 Aug 16;171(4):189-93.

PMID:
10494234
11.

Cost effectiveness of screening immigrants for hepatitis B.

Wong WW, Woo G, Jenny Heathcote E, Krahn M.

Liver Int. 2011 Sep;31(8):1179-90. doi: 10.1111/j.1478-3231.2011.02559.x. Epub 2011 Jun 14.

PMID:
21745300
12.

Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.

Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y.

Clin Infect Dis. 2014 Apr;58(8):1064-71. doi: 10.1093/cid/ciu066. Epub 2014 Feb 7.

PMID:
24510934
13.

Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.

Ethgen O, Sanchez Gonzalez Y, Jeanblanc G, Duguet A, Misurski D, Juday T.

J Med Econ. 2017 Feb;20(2):162-170. doi: 10.1080/13696998.2016.1232725. Epub 2016 Sep 21.

PMID:
27590836
14.

Impact of birth cohort screening for hepatitis C.

Asrani SK, Davis GL.

Curr Gastroenterol Rep. 2014 Apr;16(4):381. doi: 10.1007/s11894-014-0381-5.

PMID:
24595618
15.

Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C.

Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, Gross JB Jr.

Ann Intern Med. 1997 Nov 15;127(10):866-74.

PMID:
9382364
16.

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A; WEF Study Group.

J Hepatol. 2013 Oct;59(4):658-66. doi: 10.1016/j.jhep.2013.05.019. Epub 2013 May 23.

PMID:
23707373
17.
18.
19.

Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.

Robotin MC, Kansil M, Howard K, George J, Tipper S, Dore GJ, Levy M, Penman AG.

J Hepatol. 2009 May;50(5):990-8. doi: 10.1016/j.jhep.2008.12.022. Epub 2009 Feb 15.

PMID:
19303657
20.

Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.

Veldhuijzen IK, Toy M, Hahné SJ, De Wit GA, Schalm SW, de Man RA, Richardus JH.

Gastroenterology. 2010 Feb;138(2):522-30. doi: 10.1053/j.gastro.2009.10.039. Epub 2009 Oct 29.

PMID:
19879275

Supplemental Content

Support Center